Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart

Masanari Shiramoto, Tomoyuki Nishida, Ann Kathrine Hansen, Hanne Haahr, Masanari Shiramoto, Tomoyuki Nishida, Ann Kathrine Hansen, Hanne Haahr

Abstract

Introduction: Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with two added excipients (niacinamide and L-arginine) in order to obtain accelerated absorption after subcutaneous dosing. The present study compared the pharmacokinetic/pharmacodynamic characteristics of faster aspart vs IAsp in Japanese patients with type 1 diabetes.

Materials and methods: In a randomized, double-blind, cross-over design, 43 participants were given faster aspart and IAsp (0.2 U/kg single dose) at two separate dosing visits. Frequent pharmacokinetic blood sampling was carried out, and pharmacodynamics were assessed using an automated euglycemic clamp lasting for a maximum of 12 h after dosing (target 5.5 mmol/L).

Results: Faster aspart showed onset of appearance approximately twice-as-fast vs IAsp (least squares means: 3.0 vs 7.1 min; estimated treatment difference -4.1 min, 95% confidence interval [CI]: -5.0, -3.2; P < 0.001) and onset of action occurring approximately 5 min earlier (20.2 vs 25.5 min; estimated treatment difference -5.3 min, 95% CI: -8.4, -2.2; P = 0.001). Within the first 30 min post-dose, both exposure (area under the curve [AUC]IAsp,0-30 min ) and glucose-lowering effect (AUCGIR,0-30 min ) were approximately twofold greater for faster aspart vs IAsp (P < 0.001 and P = 0.002, respectively). Bioavailability of faster aspart was similar to IAsp (AUCIAsp,0-t ; estimated treatment ratio 0.99, 90% CI: 0.96-1.02), whereas the total glucose-lowering effect (AUCGIR,0-t ) was slightly lower for faster aspart vs IAsp (estimated treatment ratio 0.93, 95% CI: 0.87-0.99, P = 0.020).

Conclusions: Faster aspart showed faster onset, higher early exposure and a greater early glucose-lowering effect relative to IAsp in Japanese patients with type 1 diabetes, in accordance with previous findings in Caucasian type 1 diabetes patients.

Keywords: Japanese; Pharmacodynamics; Pharmacokinetics.

© 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Figures

Figure 1
Figure 1
Mean 2‐h pharmacokinetic profiles for fast‐acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in Japanese patients with type 1 diabetes.
Figure 2
Figure 2
Mean 2‐h pharmacodynamic profiles for fast‐acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in Japanese patients with type 1 diabetes.
Figure 3
Figure 3
Early exposure for fast‐acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in Japanese patients with type 1 diabetes including the same comparison in Caucasians13. AUC, area under the curve; CI, confidence interval; LS Mean, least squares mean; P‐value, treatment comparison of faster aspart versus IAsp within each population; Treatment ratio, faster aspart/IAsp.
Figure 4
Figure 4
Early glucose‐lowering effect for fast‐acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in Japanese patients with type 1 diabetes including the same comparison in Caucasians13. AUC, area under the curve; CI, confidence interval; GIR, glucose infusion rate; LS Mean, least squares mean; P‐value, treatment comparison of faster aspart versus IAsp within each population; Treatment ratio, faster aspart/IAsp.

References

    1. Wang JS, Tu ST, Lee IT, et al Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011; 27: 79–84.
    1. Scheen AJ, Schmitt H, Jiang HH, et al Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. Diabetes Metab 2015; 41: 216–222.
    1. Shimizu H, Uehara Y, Okada S, et al Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin‐treated Japanese diabetic patients. Endocr J 2008; 55: 753–756.
    1. Woerle HJ, Neumann C, Zschau S, et al Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280–285.
    1. Fukushima M, Usami M, Ikeda M, et al Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross‐sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831–835.
    1. Horikawa C, Yoshimura Y, Kamada C, et al Dietary intake in Japanese patients with type 2 diabetes: analysis from Japan Diabetes Complications Study. J Diabetes Investig 2014; 5: 176–187.
    1. Ikeda S, Crawford B, Sato M. Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data. BMC Health Serv Res 2016; 16: 6.
    1. Home PD. The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences. Diabetes Obes Metab 2012; 14: 780–788.
    1. Home PD. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab 2015; 17: 1011–1020.
    1. Buckley ST, Kildegaard J, Høiberg‐Nielsen R, et al Mechanistic analysis into the mode(s) of action of niacinamide in faster‐acting insulin aspart. Diabetes Technol Ther 2016; 18(Suppl 1): A116–A117.
    1. Heise T, Hövelmann U, Brøndsted L, et al Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 2015; 17: 682–688.
    1. Heise T, Stender‐Petersen K, Hövelmann U, et al Pharmacokinetic and pharmacodynamic properties of faster‐acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clinical Pharmacokinet 2017; 56: 649–660.
    1. Heise T, Pieber TR, Danne T, et al A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in adults with type 1 diabetes. Clinical Pharmacokinet 2017; 56: 551–559.
    1. Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med 2011; 4: 827–835.
    1. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47: 7–20.
    1. Kaku K, Matsuda M, Urae A, et al Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid‐acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 2000; 49: 119–126.
    1. World Medical Association . Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 59th WMA General Assembly, Seoul, October 2008.
    1. Ministry of Health and Welfare Ordinance on Good Clinical Practice (MHW Ordinance No. 28). March 27, 1997. Available from: Accessed May 23, 2017. (Japanese)
    1. American Diabetes Association . Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycaemia. Diabetes Care 2005; 28: 1245–1249.
    1. Fieller EC. Some problems in interval estimation. J R Stat Soc Series B Stat Methodol 1954; 16: 175–185.
    1. European Medicines Agency . Committee for Medicinal Products for Human Use. Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Corr. 20 January 2010. Available from: Accessed May 23, 2017.
    1. Food and Drug Administration . Code of Federal Regulations. 21 CFR Part 320. Bioavailability and Bioequivalence Requirements. Available from: Accessed May 23, 2017.
    1. Russell‐Jones D, Bode B, de Block C, et al Fast‐acting insulin aspart improves glycemic control in basal‐bolus treatment for type 1 diabetes: results of a 26‐week multicenter, active‐controlled, treat‐to‐target, randomized, parallel‐group trial (Onset 1). Diabetes Care 2017; 40: 943–950.
    1. Bowering K, Case C, Harvey J, et al Faster aspart versus insulin aspart as part of a basal‐bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. Diabetes Care 2017; 40: 951–957.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren